Prenatal Application of the Individualized Fetal Growth Reference by Zhang, Jun et al.
American Journal of Epidemiology
Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health 2011.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Vol. 173, No. 5
DOI: 10.1093/aje/kwq411
Advance Access publication:
January 20, 2011
Practice of Epidemiology
Prenatal Application of the Individualized Fetal Growth Reference
Jun Zhang*, Rafael Mikolajczyk, Jaceteshwar Grewal, Gila Neta, and Mark Klebanoff
* Correspondence to Dr. Jun Zhang, Epidemiology Branch, National Institute of Child Health and Human Development, National
Institutes of Health, Building 6100, Room 7B03, Bethesda, MD 20892 (e-mail: zhangj@mail.nih.gov).
Initially submitted June 21, 2010; accepted for publication October 27, 2010.
The individualized reference for deﬁning small for gestational age (SGA) at birth has gained popularity in recent
years. However, its utility on fetal assessment has not been evaluated. The authors compare an individualized with
an ultrasound reference in predicting poor perinatal outcomes. Data from a large clinical trial in predominantly white
US women (1987–1991) with singleton pregnancies (n ¼ 9,526) were used. The individualized reference classiﬁed
fewer SGA fetuses than the ultrasound reference, but the risks of adverse outcomes were similar between fetuses
classiﬁed by both references. The risk increased substantially only when the percentiles fell below the 5th per-
centile (likelihood ratio positive at birth ¼ 2.68 (95% conﬁdence interval (CI): 2.00, 3.58) and 3.13 (95% CI: 2.34,
4.18) for ultrasound and individualized references, respectively). SGA fetuses deﬁned by either the individualized
or ultrasound reference alone had risk ratios of adverse outcomes of 1.91 (95% CI: 0.77, 4.77) and 1.18 (95% CI:
0.37, 3.77), respectively, compared with normal fetuses (the difference between these 2 risk ratios, P ¼ 0.71). The
authors conclude that neither the ultrasound-based nor the individualized reference does well in predicting adverse
perinatal outcomes. The 5th percentile may be a better cutpoint than the 10th percentile in deﬁning SGA.
fetal growth retardation; infant, small for gestational age; perinatal mortality
Abbreviations: CI, conﬁdence interval; LMP, last menstrual period; RADIUS, Routine Antenatal Diagnostic Imaging with Ultra-
sound; SGA, small for gestational age.
Deﬁning fetal growth restriction has been a longstanding
challenge. Currently, most clinicians and researchers use
small for gestational age (SGA) (i.e., the smallest 10% of
fetuses or newborns at a given gestational week) as a surro-
gate for fetal growth restriction (1). One of the primary de-
ﬁciencies of the current deﬁnition of fetal growth restriction
is that it is based on an absolute fetal size, irrespective of
maternal and fetal genetic and physiologic factors. For ex-
ample, fetuses from a large white mother and a small Asian
mother are both assessed by the same criterion, which could
deem one fetus to be SGA and the other to be within the
normal range, even though what is normal can be expected
to differ according to maternal characteristics. As a result,
both under- and overdiagnosis of fetal growth restriction
may occur, which has signiﬁcant clinical implications.
Clinicians and researchers have increasingly recognized
that fetal growth should be evaluated according to the extent
to which a particular fetus has fulﬁlled its growth potential
for a given maternal and fetal proﬁle (2). Brenner et al. (3)
were the ﬁrst to advance this notion of an individualized
reference, proposing an adjustment for race, sex, and parity
when assessing birth weight by gestational age. Gardosi
et al. (4) later developed a detailed methodology to auto-
mate the procedure that used a fetal weight curve and ad-
justed for maternal race, parity, pre- or early pregnancy
weight and height, and infant’s sex. Their methodology con-
tinues to gain greater acceptance (5).
Currently,3typesofSGAreferencesarecommonlyused—
references based on birth weight (e.g., by Alexander et al.)
(6), estimated fetal weight (e.g., by Hadlock et al.) (7), and
individualized reference (4). The birth weight reference is
ﬂawed in early gestation weeks because babies born preterm
are often growth restricted. That segment in the birth weight
reference has artiﬁcially lower percentile limits (8); that
is, SGA is likely to be underdiagnosed in early gestation.
Several past studies found that infants classiﬁed by the in-
dividualized reference as SGA had a signiﬁcantly higher
overall mortality and morbidity than SGA infants classiﬁed
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mortality among infants classiﬁed as SGA by the individu-
alized reference is largely due to the inclusion of more pre-
term births in this group (8, 14). Given the important
deﬁciency with the birth weight reference in preterm births,
researchers are now seeking better references.
The individualized reference adopts the fetal weight ref-
erence as the base but adjusts for other factors (4). Some
studies of the risk of stillbirth (15) and neonatal death (16)
have suggested that the advantages of the individualized
reference, relative to a simple ultrasound-based fetal weight
reference (i.e., without adjustment for maternal or fetal
characteristics), are rather limited. It remains unclear
whether the individualized reference is superior if perinatal
morbidity (instead of mortality) is used as the outcome.
Although assessment of newborn size at birth is important
for pediatric care and research for long-term outcomes, rec-
ognizing SGA in utero is as crucial for obstetric care and
research on fetal programming. Thus, existing research
leaves open the questions about how best to identify SGA
fetuses either in utero or at birth that have a higher risk of
exhibiting adverse outcomes. No study to our knowledge
has evaluated the prenatal utility of individualized refer-
ence. Therefore, this paper focuses on the ultrasound esti-
mated fetal weight and compares the fetal weight and
individualized references with regard to their ability to pre-
dict perinatal outcomes.
MATERIALS AND METHODS
The Routine Antenatal Diagnostic Imaging with Ultra-
sound (RADIUS) trial was a multicenter study of pregnant
women at low risk for adverse outcomes. The trial was
designed to test the hypothesis that routine screening with
standardized ultrasonography on 2 occasions would reduce
perinatal morbidity and mortality. A detailed description of
the trial is provided elsewhere (17). Brieﬂy, from November
1987 to May 1991, pregnant women who were aged 18
years or older, who spoke English, whose last menstrual
period (LMP) was known within 1 week, and whose gesta-
tional age was less than 18 weeks at recruitment were po-
tentially eligible for the study. The study excluded women
who had a previous stillbirth, prior SGA infant, irregular
menstrual cycles, discrepancy between uterine size and
dates of more than 3 weeks, diabetes, chronic hypertension,
or chronic renal disease. In total, the RADIUS trial recruited
15,151 women, including 15,018 singleton pregnancies;
90% of the subjects were white.
Eligible women were randomly assigned to either the
ultrasound screening group or the control group. Women
in the former group underwent sonographic examinations
at both 15–22 and 31–35 weeks of gestation. All of the study
participants, regardless of group, could undergo ultrasonog-
raphy at any time for medical or obstetric indications, as
identiﬁed by their physicians. The standardized fetal bio-
metry included biparietal diameter, head circumference, ab-
dominal circumference, and femur length. Women were
interviewed at recruitment, and information on demographic
characteristics and reproductive history was recorded. Ante-
partum,intrapartum,andneonatalinformationwas abstracted
from the antenatal medical records and from inpatient hospi-
tal records.
At enrollment, each woman reported the ﬁrst day of her
LMP. We used ultrasound measurements of the ﬁrst fetal
biometry to validate the gestational age, relying on Had-
lock’s formula (18) to calculate an ultrasound-based LMP.
If the self-reported LMP and ultrasound-based LMP dif-
fered by more than 7 days for women prior to 21 weeks of
gestation, or by more than 10 days for gestational ages
between 21 and 26 weeks, the ultrasound-based LMP
was substituted for the self-reported LMP. Gestational
age at delivery was calculated according to the corrected
LMP. Ultrasound measurements at 30 weeks or later were
used to calculate the estimated fetal weight on the basis of
head and abdominal circumferences and femur length
(19).
We selected women who had an ultrasound examination
at 30 weeks of gestation or later because that is when most
ultrasound examinations in late gestation were done in this
study. A total of 6,787 and 2,027 women had at least 1
ultrasound scan between 30–33 weeks of gestation and at
34 weeks or later, respectively. The sample used in our
analysis included a total of 9,526 births delivered at 30
weeks or later (some of them had birth weight, but not
estimated fetal weight at 30 weeks or after). All of the sub-
jects had complete information on birth weight, gestational
age, maternal race, parity, infant’s sex, maternal prepreg-
nancy weight and height, and perinatal morbidity and
mortality.
To deﬁne SGA, we applied 2 widely used references to
our study population. The ﬁrst was an ultrasound-based fetal
weight reference (7), which was created on the basis of
a cross-sectional cohort of predominantly low-risk white
women in the United Sttates with a normal perinatal out-
come. The second was an individualized reference, which
adjusted the fetal weight reference for maternal race/
ethnicity, parity, prepregnancy or early pregnancy height
and weight, and infant’s sex in the US population (www.
gestation.net) (20). We used the 10th and 5th percentiles in
each reference and compared the proportion of infants
classiﬁed by these references as SGA.
In the RADIUS trial, the list of adverse perinatal out-
comes encompassed the following: fetal death or neonatal
death up to 28 days of age, grade IV retinopathy of pre-
maturity, bronchopulmonary dysplasia, mechanical ven-
tilation required for more than 48 hours, necrotizing
enterocolitis, intraventricular hemorrhage, subdural or cere-
bral hemorrhage, neonatal seizure, placement of chest tube,
neonatal sepsis, oxygen required for more than 48 hours,
birth trauma, or a stay of more than 5 days in a special care
nursery. Because of the small number of subjects with se-
vere adverse outcomes, we created a composite outcome
that includes any of the above conditions. We compared
the incidence of the composite outcome among infants clas-
siﬁed by both references and, for each reference, we calcu-
lated the likelihood ratio (21) in predicting the adverse
outcome. Finally, because this is a secondary data analysis
using deidentiﬁed data, an institutional review board exemp-
tion was obtained.
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Table 1 presents the proportions of SGA infants that were
based on different reference types. The ultrasound reference
classiﬁed more SGA infants (<10th percentile): 8% at
30–33 weeks, 13% at  34 weeks, and 11% at birth. The
numbers of SGA infants that the individualized reference
identiﬁed are as follows: 6%, 10%, and 8%, respectively.
Table 1 also shows that thevast majority of adverse perinatal
outcomes occurred in fetuses/infants weighing above the
10th percentile of either reference. The ultrasound and in-
dividualized references yielded a very similar incidence of
adverse outcomes in SGA infants (<10th percentile overall)
(all P > 0.05). The results also suggest that the incidence of
adverse outcome is substantially higher only when the
weight falls below the 5th percentile. The likelihood ratios
indicate that only weight below the 5th percentile may have
predictive power for adverse outcomes. These ﬁndings are
robust even when we separate preterm and term births (re-
sults not shown).
We then examined the association between weight below
the 5th percentile, based on the ultrasound and individual-
ized references, and the incidence of adverse outcomes
(Table 2). The SGA cases classiﬁed by these 2 references
overlap considerably (70%–77% of SGA cases). The cases
identiﬁed by both references had a much higher risk of
adverse outcomes than those identiﬁed by just 1 of the ref-
erences and those not classiﬁed as SGA cases by either
Table 1. Classiﬁcation of Small-for-Gestational-Age Infants by Different Reference Types and Incidence of Perinatal Mortality and Morbidity,
United States, 1987–1991
Fetuses/Infants Below Certain
Percentiles by Reference Type Incidence of Adverse Outcomes Predictive Value
Ultrasound Individualized Ultrasound Individualized Ultrasound Individualized
No. % No. % No. % No. % LR 95% CI LR 95% CI
Estimated fetal
weight at
30–33 weeks
(n ¼ 6,787)
>10th percentile 6,268 92 6,370 94 224 3.6 232 3.6 0.93 0.89, 0.98 0.95 0.91, 0.99
5th–10th
percentile
326 5 211 3 14 4.3 5 2.4 1.13 0.67, 1.90 0.61 0.25, 1.47
<5th percentile 193 3 206 3 21 10.9 22 10.7 3.08 1.99, 4.76 3.01 1.97, 4.61
Estimated fetal
weight at 34
weeks or later
(n ¼ 2,027)
>10th percentile 1,764 87 1,823 90 63 3.6 66 3.6 0.98 0.89, 1.08 0.99 0.91, 1.07
5th–10th
percentile
126 6 76 4 6 4.8 3 4.0 1.32 0.60, 2.90 1.08 0.35, 3.36
<5th percentile 137 7 128 6 5 3.7 5 3.9 1.00 0.42, 2.37 1.07 0.45, 2.54
Birth weight
(n ¼ 9,526)
>10th percentile 8,454 89 8,737 92 310 3.7 322 3.7 0.90 0.86, 0.95 0.91 0.87, 0.95
5th–10th
percentile
629 6 395 4 31 4.9 18 4.6 1.23 0.87, 1.74 1.13 0.71, 1.79
<5th percentile 443 5 394 4 45 10.2 46 11.7 2.68 2.00, 3.58 3.13 2.34, 4.18
Abbreviations: CI, conﬁdence interval; LR, likelihood ratio.
Table 2. Classiﬁcation Overlap Between Ultrasound and Individualized Reference Types and Incidence of
Adverse Perinatal Outcomes, United States, 1987–1991
Weight Below the
5th Percentile by
Ultrasound-estimated
Fetal Weight at ‡30 Weeks Birth Weight
No. % Incidence, % RR 95% CI No. % Incidence, % RR 95% CI
Neither reference 7,756 95.4 3.6 1.0 8,989 94.4 3.7 1.0
Ultrasound
reference only
72 0.9 4.2 1.18 0.37, 3.77 130 1.4 3.9 1.04 0.42, 2.55
Individualized
reference only
76 0.9 6.6 1.91 0.77, 4.77 94 1.0 7.5 2.09 0.96, 4.54
Both references 226 2.8 9.7 2.92 1.85, 4.61 313 3.3 12.8 3.80 2.68, 5.39
Abbreviations: CI, conﬁdence interval; RR, risk ratio.
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subjects classiﬁed as SGA only by the individualized refer-
ence seem to have a higher risk ratio of adverse outcomes
(risk ratio ¼ 1.91, 95% conﬁdence interval (CI): 0.77, 4.77)
than those classiﬁed as SGA by the ultrasound reference
alone (risk ratio ¼ 1.18, 95% CI: 0.37, 3.77). A similar
pattern of results was observed for birth weight. However,
the differences in corresponding risk ratios were not statis-
tically signiﬁcant (P ¼ 0.71 and P ¼ 0.23, respectively).
Furthermore, because of substantial overlap, the number of
extra cases that can be identiﬁed by the individualized ref-
erence is limited.
DISCUSSION
Our study, using data from the RADIUS trial, shows that
the 5th percentile is a better cutoff point for deﬁning SGA
than the 10th percentile with regard to its ability to predict
adverse perinatal outcomes. However, even with the 5th
percentile, neither the ultrasound nor the individualized ref-
erence for SGA has high predictive power. With advanced
perinatal care, the majority of infants whose weight is below
the 10th percentile survivewell without any signiﬁcant mor-
bidity and mortality. Our study shows that the risk of ad-
verse perinatal outcomes increased meaningfully only after
the weight falls below the 5th percentile. This ﬁnding raises
the question of whether in a contemporary population SGA
should be redeﬁned as having a weight below the 5th per-
centile rather than the traditional 10th percentile.
It is well established that race, parity, sex, and maternal
prepregnancy height and weight inﬂuence fetal weight. For
example, male fetuses are, on average, 100 g heavier than
female fetuses at birth (22). The mean birth weight of white
infants is approximately 200 g greater than that of black
infants (22). In principle, therefore, the individualized ref-
erence should be able to assign a fetus/infant to a more
appropriate weight percentile than a simple ultrasound-
based reference. Fine tuning the weight percentile, however,
does not seem to yield substantial gains as far as predicting
adverse perinatal outcomes.
Several reasons may explain this phenomenon. First, the
likelihood of being classiﬁed by both references as being
below the 5th percentiles is high; that is, there is a large
overlap. The ﬁne tuning affects mostly the borderline SGA
cases. These cases tend to have lower mortality and morbid-
ity than the more severe cases.
Second, errors in the ultrasound-based estimated fetal
weight may have further reduced the potential improve-
ment. These ﬁndings are consistent with those of previous
studies (15, 16).
Third, the correlation between weight percentiles and risk
of adverse perinatal outcomes is disappointingly low. Sim-
ilar to previous studies, the current study found that the vast
majority of adverse perinatal outcomes occurred in fetuses/
infants with weights above the 10th percentile (Table 1)
(23). Conversely, the risk of adverse outcomes increases
substantially only when the estimated fetal weight or birth
weight is below the 5th percentile in both preterm and term
births. Thus, any improvement in percentile assignment of-
fered by the individualized reference is further offset by the
low correlation between the percentile and adverse out-
comes. These deﬁciencies may explain why the individual-
ized reference does not provide a substantial overall
advantage over the simple ultrasound reference in our study.
One could argue that the conditions included in the peri-
natalcomposite outcome are notspeciﬁc todisorders offetal
growth and that the improved assignment of weight percen-
tiles by the individualized reference may still be important
for more subtle and long-term effects, such as child neuro-
development and adult diseases in later life. Fetal growth
restriction is a consequence of many causes and an indicator
of compromised fetal status. Thus, fetal growth restriction
itself does not necessarily cause adverse perinatal outcomes
but is associated with a wide variety of perinatal mortality
and morbidity. We selected a number of perinatal outcomes
that are clinically important and priority concerns of both
obstetricians and neonatologists (24, 25). Consequently,
these outcomes should be the ‘‘gold standard’’ in assessing
the prenatal utility of these references, even though they
may not be good indicators for long-term effects.
As in previous studies (15, 16), our study population also
has the limitation of being relatively homogeneous—a pre-
dominantly white population. It is reasonable to question
whether the advantage of the individualized reference mainly
reﬂects in a racially diverse population. Further studies with
a diverse population are needed to address this issue. None-
theless, ﬁndings from previous studies and ours suggest that
adjusting for other characteristics (namely, maternal height
and weight, parity, and sex of the infant) in the individualized
reference may not improve the classiﬁcation as much as pre-
viously reported when the individualized reference was com-
pared with a birth weight reference (9–13).
At the same time, our study has several advantages over
existing published research. For one, we used data from
a large, carefully conducted prospective trial. More impor-
tantly, our study provides the ﬁrst evidence using ultrasound-
based estimated fetal weight, which is more relevant to
obstetric practice than the birth weight data examined in past
studies.
In conclusion, neither the ultrasound nor the individual-
ized references for SGA do well in predicting adverse peri-
natal outcomes in pregnancies of predominantly white
women. Research in a racially diverse population is needed
to demonstrate whether the individualized reference has
substantial advantages over the simple ultrasound reference.
Finally, the 5th percentile may be a better cutpoint than the
10th percentile in deﬁning SGA.
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